|
|
|
ONLINE FEATURES
Book Reviews
BW Video
Columnists
Interactive Gallery
Newsletters
Past Covers
Philanthropy
Podcasts
Special Reports
BLOGS
Auto Beat
Bangalore Tigers
Blogspotting
Brand New Day
Byte of the Apple
Economics Unbound
Eye on Asia
Fine On Media
Green Biz
Hot Property
Investing Insights
Management IQ
NEXT: Innovation
NussbaumOnDesign
Tech Beat
Working Parents
TECHNOLOGY
J.D. Power Ratings
Product Reviews
Tech Stats
Wildstrom: Tech Maven
AUTOS
Home Page
Auto Reviews
Classic Cars
Car Care & Safety
Hybrids
INNOVATION
& DESIGN Home Page Architecture Brand Equity Auto Design Game Room SMALLBIZ Smart Answers Success Stories Today's Tip INVESTING Investing: Europe Annual Reports BW 50 S&P Picks & Pans Stock Screeners Free S&P Stock Report SCOREBOARDS Hot Growth 100 Mutual Funds Info Tech 100 S&P 500 B-SCHOOLS Undergrad Programs MBA Blogs MBA Profiles MBA Rankings Who's Hiring Grads |  |
APRIL 4, 2005
Schein Gets Over The Flu  When Britain ordered Chiron (CHIR
) to halt output of its influenza vaccine last October, one company that got clobbered was Henry Schein (HSIC
), the world's top distributor of health-care goods -- and No. 1 in flu vaccines in the U.S. Schein supplies medicines and services to 400,000 doctors, dentists, and vets. Chiron's woes shaved 50 cents a share off Schein's fourth-quarter earnings. Its stock -- at 40 last April -- swooned to 28.80 by Oct. 19. But Schein has rallied, to 40 on Mar. 7, before easing to 36. ``Fourth-quarter earnings were impressive, as other products [especially dental] continued to grow rapidly,'' says John Maloney, president of M&R Capital Management, which owns shares. The flu issue is almost resolved. On Mar. 2, Britain lifted the Chiron suspension. The Food & Drug Administration is expected to follow suit by summer, says Maloney. He notes Schein has asked other makers -- Sanofi-Aventis (SNY
), ID Biomedical (IDBE
), MedImmune (MEDI
), and GlaxoSmithKline (GSK
) -- for vaccines in 2005 and 2006. Suey Wong of securities firm Robert W. Baird, which has done banking for Schein, sees profits of $2.03 a share on sales of $4.8 billion in 2005, and $2.31 on $5.2 billion in 2006, vs. 2004's $1.53. Wong rates Schein ``outperform,'' with a target of 46. He sees it as one of 2005's best performers.
Note: Unless otherwise noted, neither the sources cited in Inside Wall Street nor their firms hold positions in the stocks under discussion. Similarly, they have no investment banking or other financial relationships with them.  By Gene G. Marcial
BW MALL
SPONSORED LINKS
Get BusinessWeek directly on your desktop with our RSS feeds.
Buy a link now! Add BusinessWeek news to your Web site with our headline feed. Click to buy an e-print or reprint of a BusinessWeek or BusinessWeek Online story or video. To subscribe online to BusinessWeek magazine, please click here. Learn more, go to the BusinessWeekOnline home page  | | |
 Copyright 2005, by The McGraw-Hill Companies Inc. All rights reserved.Terms of Use | Privacy Notice |
Printer-Friendly Version